Associate Professor, Medicine, University of Wisconsin Medical School
Oncology
Dr. Anne M. Traynor, MD
|
|
Give Review
Anne Traynor works in the field of Oncology. He went to University of North Carolina at Chapel Hill School of Medicine. University of North Carolina at Chapel Hill School of Medicine is a top medical university. University of North Carolina at Chapel Hill School of Medicine is ranked 22/2 in Research/PrimaryCare. He has 1 awards "Meaningful Use Stage 1 Certification". Anne M. Traynor, MD is also a published MD. He has 38 paper published. The most recent paper is: Bendamustine+rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: AWiscon...
Publications
- A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid Tumors.
- Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wiscon...
- Phase 1 Trial of Bevacizumab With Concurrent Chemoradiation Therapy for Squamous Cell Carcinoma of the Head and Neck With Exploratory Functional Imaging of Tumor Hypox...
- Strategies to prevent brain metastasis in high-risk non-small-cell lung Cancer: lessons learned from a randomized study of maintenance temozolomide versus observation.
- Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a wisconsin oncology network study.
- A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced Cancer.
- Alkylphosphocholine analogs for broad-spectrum Cancer imaging and therapy.
- Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung Cancer: a Wisconsin Oncology Network Phase II study.
- Metastasis of primary lung carcinoma to the breast: a Systematic review of the literature.
- A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
- Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung Cancer cells enabled by the VerIFAST platform.
- Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung Cancer an Eastern Cooperative Oncology Group Study (E3503).
- Feasibility of 4 Cycles of Docetaxel and Cyclophosphamide Every 14 Days as an Adjuvant Regimen for Breast Cancer: A Wisconsin Oncology Network Study.
- Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in Non-Small-Cell Lung Cancer.
- Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.
- A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung Cancer.
- Increased local failure risk with prolonged radiation treatment time in head and neck Cancer treated with concurrent chemotherapy.
- Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung Cancer.
- An eHealth system supporting palliative care for patients with non-small cell lung Cancer: A randomized trial.
- Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast Cancer: a Wisconsin Oncology Network trial.
- A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract Cancer: a Wisconsin oncology network study.
- A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients: Eastern Cooperative Onco...
- Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer.
- Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies.
- Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electr...
- A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid Tumors.
- Comprehensive IMRT plus weekly cisplatin for advanced head and neck Cancer: the University of Wisconsin experience.
- A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung Cancer: Eastern Cooperative Oncology Group Study 1503.
- Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung Cancer: a Wisconsin Oncology Network phase II study.
- Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung Cancer in patients at least 70 years old: a wisconsin oncology ne...
- Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
- Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid Tumors treated with Triapine.
- Phase II study of daily Oral perifosine in patients with advanced soft tissue sarcoma.
- Temozolomide as prophylaxis for brain metastasis in non-small cell lung Cancer.
- Mutation and polymorphism in the EGFR-TK domain associated with lung Cancer.
- Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung Cancer.
- Adjuvant therapy in the treatment of non-small-cell lung Cancer.
Schools
University Of North Carolina Chapel Hill School Of Medicine
Mary Imogene Bassett Hospital
University Iowa Hosps and Clinics
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- American Enterprise Group
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Preferred Plus POS
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Cross Accord
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care of Missouri PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- Group Health Cooperative
- Choice Care PPO
- Medicare MCR
- Thrivent Financial
- United Healthcare
Awards
- Meaningful Use Stage 1 Certification
Education
-
University of Iowa Hospitals and Clinics -
University of North Carolina at Chapel Hill School of Medicine
Hospital
-
University of Wisconsin Hospital and Clinics
Drug Facts
| NPI NUMBER | 1629039094 | |
| NPPES Provider LastName | TRAYNOR | |
| NPPES Provider FirstName | ANNE | |
| NPPES Provider ZIPCode | 53792 | |
| NPPES Provider State | WI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 633.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 169.0 | |
| Percent Opioid Claims | 26.7 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1629039094 |
| Last Name Of The Provider | TRAYNOR |
| First Name Of The Provider | ANNE |
| View All |
Similar Doctors
|
|
Dr. Murtuza M. Rampurwala, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert B. Hegeman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. H I. Robins, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Howard H. Bailey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Glenn Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George Wilding, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James F. Cleary, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Douglas G. McNeel, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|